News

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read

EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The phase 2 DAVIO 2 trial of EYP-1901, a sustained delivery maintenance treatment for wet age-related macular degeneration, demonstrated positive top-line results and successfully met its primary endpoint.

Combining Vorolanib and Durasert E

This innovative treatment involves combining vorolanib, a selective tyrosine kinase inhibitor, with bioerodible Durasert E. The trial also achieved noteworthy secondary endpoints, including a remarkable 80% reduction in treatment burden and nearly two-thirds of participants being able to go supplement-free for up to six months. Additionally, over 80% of participants received either zero or only one supplement within the six-month period.

Looking Ahead: VERONA Trial

EyePoint Pharmaceuticals is not slowing down and has its sights set on reaching other clinical milestones with its treatment. The company is set to initiate the phase 2 VERONA trial in diabetic macular edema, projected to commence early next year. This exciting development marks another step forward in advancing the field of ophthalmology.

For more information on this groundbreaking research, please contact EyePoint Pharmaceuticals directly.

Related posts
News

HP Inc.'s Fiscal Results Insights

1 Mins read
HP Inc.’s stock experienced a 4% decline in extended trading on Wednesday following the release of their latest fiscal results that were…
News

Lawsuit Over Crown Castle Governance Rights

1 Mins read
Overview Crown Castle co-founder Ted Miller, along with his investment vehicle, has filed a lawsuit challenging an agreement between the company’s board…
News

The Demise of Defined Benefit Pension Plans

3 Mins read
Different Perspectives on ERISA’s Impact While many view ERISA as a contributing factor to the decline of defined-benefit (DB) plans, others argue…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 85 = 89